Cebix's Long-Acting C-Peptide Ersatta? Has Potential In Multiple Chronic Complications Of Diabetes

Podiatry Arena Cebix's Long-Acting C-Peptide Ersatta? Has Potential In Multiple Chronic Complications Of Diabetes

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

Cebix's Long-Acting C-Peptide Ersatta? Has Potential In Multiple Chronic Complications Of Diabetes

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

25th June 2011, 02:30 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 10,128

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 19 Times in 19 Posts

Cebix's Long-Acting C-Peptide Ersatta? Has Potential In Multiple Chronic Complications Of Diabetes

Podiatry Arena members do not see these ads

Cebix Incorporated announced that preclinical data for its long-acting form of C-peptide, Ersatta? (CBX129801), demonstrated a half-life of three days as compared to one hour for native C-peptide. Ersatta halted the impairment in nerve conduction velocity, a measure of the rate at which electrical signals travel through the nerves, in an animal model of diabetic peripheral neuropathy...

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Switch to Linear Mode Switch to Hybrid Mode Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Investigational Ultra-long-acting Insulin Degludec Reduces Hypoglycaemia And Improves Long-term Control In Patients With Type 1 And Type 2 Diabetes	RSSFeedBot	Latest Diabetes Medicine Research & News	0	24th June 2011 03:30 PM
Phase 2 Data For Ultra-Long-Acting Insulin Degludec Shows The Potential To Effectively Lower Blood Sugar, Including When Used Three Times A Week	RSSFeedBot	Latest Diabetes Medicine Research & News	0	10th July 2010 04:00 AM
Multiple Surgery Complications	RSSFeedBot	Foot Health Forum	0	27th June 2010 12:20 PM
Long-acting insulin analogues in type 1 diabetes: No proof of additional benefit, German study finds	RSSFeedBot	Latest Diabetes Medicine Research & News	0	12th May 2010 01:10 PM
Novo Nordisk Starts Phase I Trial With Long-Acting Oral GLP-1 Analogue	RSSFeedBot	Latest Diabetes Medicine Research & News	0	13th January 2010 09:20 PM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 06:02 AM.

User Name		Remember Me?
Password